TLSA - Tiziana Life Sciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

45.61M

Cash

18.12M

Avg Qtr Burn

-4.904M

Short % of Float

1.05%

Insider Ownership

43.47%

Institutional Own.

1.07%

Qtr Updated

12/31/22

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Foralumab Details COVID-19	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Milciclib (pan-CDK inhibitor) Details Solid tumor/s, Hepatocellular carcinoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foralumab (anti-CD3 mAb) Details Multiple sclerosis	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Foralumab (anti-CD3 mAb) Details Crohns disease	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Intranassal Foralumab (anti-CD3 mAb) Details Neurodegenerative disease, Alzheimer's disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.